A better conversation starts with one difficult decision.
An independent pharmacy owner needs to understand why a promising service never became dependable work. A medicines team needs to know why an approved opportunity keeps returning to the next meeting. A pharmacy group wants to distinguish a repeatable improvement from a good week at one branch. Bring the problem that matters to you. A guided PHARMORIS briefing should make that problem clearer before asking you to consider a platform.
PHARMORIS is under controlled development. This is an invitation to a guided, non-clinical discussion using representative material and the current development scope. Any screens or examples shown would be identified by their status; an illustration would not stand in for a working deployment.
Find the point where good intentions lose momentum
Describe the last time the workflow stalled. Perhaps the source was difficult to interpret, the next owner was unclear, a handover went unanswered or the financial assumptions could not survive local scrutiny. The useful detail is the sequence: what arrived, who considered it, what was decided and what happened afterwards. A process description is enough for an initial conversation. Patient-identifiable records, commercial contracts, passwords and confidential source material should stay in your organisation.
Illustrative briefing photography. An initial discussion begins qualification and information scoping; these stock models are not NEUVIOR staff, investors or a record of a financing commitment.
Pressmaster · Businessmen Discussing Information on Tablet in OfficeEnvato Elements commercial licence
Source and image notes
Full frame retained; EXIF orientation honoured, proportionally resized and encoded as WebP. No crop, creative colour grading, compositing or generative changes.
Choose the perspective that makes the session useful
For an owner, the question might be whether a service deserves staff time and investment. For a pharmacist, it might be whether the evidence and responsibilities can be understood during a busy day. For a hospital or commissioner, it may concern the relationship between a provider's incentives and the system's costs. We would agree the perspective first, because a workflow can appear attractive to one participant while moving cost or work to another.
Follow one example from evidence to review
A representative example would trace the original question, the material available to review, the person with authority to decide, the work that decision creates and the evidence needed to revisit it. Missing information should remain visible. An unresolved ownership question should remain unresolved until a person can answer it. The purpose is to examine whether the PHARMORIS direction could improve the continuity of that work, rather than race through a catalogue of features.
Guided briefing
What should a PHARMORIS briefing leave behind?
A guided discussion should clarify a difficult workflow before it presents a platform. Move through a representative briefing from the current task to the comparison worth making. The resulting questions help prepare a scoped conversation; this interactive guide is not an operational software demonstration, customer evaluation or automatic access offer.
Editorial decision model, not measured NEUVIOR results.
Bring a problem and the present alternative
Preparation needs a recurring task and a clear account of ordinary practice. That gives the conversation something meaningful to compare against. A broad wish to optimise medicines is less useful than a description of who reviews a particular question and where the handover becomes difficult.
Prepare one task, owner and current approach.
The stalled task
Describe the last time the work became difficult: what arrived, who considered it and what happened next. An honest process account includes the parts already handled well. It should stay non-confidential and avoid patient records, commercial contracts, credentials or unpublished source material.
- Choose the viewpoint
Current task, existing method and point of friction.
A useful next stepWhere did the last example lose momentum?
A useful briefing leaves a clearer comparison and next decision, even when further work is not justified.
Leave with a decision brief you can challenge
The proposed briefing artefact is a short workflow decision brief: the operating question, today's approach, the point of friction, the relevant roles, permitted inputs and one candidate measure. It would distinguish information you supplied from assumptions that still need testing. It would also record a reason to stop where the problem is already well served, requires access we cannot establish or depends on a capability that has not been evidenced. Its format and scope would be agreed before any commissioned work.
Make a pilot earn its place
A useful evaluation needs a comparison with competent existing practice. That might be the current meeting pack, an established review template or the organisation's existing service dashboard. We would propose examining the checking time, missing information, clarity of ownership and effort of the handover, alongside any claimed time benefit. Success criteria and a stopping decision should be written before the exercise, so an attractive demonstration cannot quietly redefine what success meant.
Agree the next commitment, including the cost of learning
An initial discussion should establish whether a more detailed scoping exercise is worthwhile. A later proposal would need to identify the work, fee where applicable, access conditions, responsibilities and deliverable. There is no presumed purchase or deployment at the end of a briefing. The next decision may be to prepare a bounded evaluation, narrow the use case, seek a different specialist or leave the workflow unchanged. Knowing which of those is sensible is already a useful commercial outcome.
Bring the question you want answered
Tell us your setting, the decision you hold and where progress becomes difficult. Include the existing approach you would want PHARMORIS compared against. We can then frame a conversation around the evidence needed for your next decision, with the appropriate clinical, operational or assurance colleagues involved.
Useful reading before the discussion
NICE's evidence standards framework provides an external reference for thinking about effectiveness and economic value. It does not constitute NICE endorsement of PHARMORIS. Our proposed briefing and evaluation criteria on this page are NEUVIOR's discussion approach, rather than results of a completed customer study.
